Sinopharm Group Co. Ltd (X2S) - Total Liabilities

Latest as of December 2025: €256.20 Billion EUR ≈ $299.53 Billion USD

Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) has total liabilities worth €256.20 Billion EUR (≈ $299.53 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Sinopharm Group Co. Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.

Sinopharm Group Co. Ltd - Total Liabilities Trend (2013–2025)

This chart illustrates how Sinopharm Group Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Sinopharm Group Co. Ltd (X2S) total assets.

Sinopharm Group Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Sinopharm Group Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
First Merchants Corporation NASDAQ:FRME	USA	$16.56 Billion
Tongling Jingd SHG:600577	China	CN¥10.25 Billion
Zhejiang Kaishan Compressor SHE:300257	China	CN¥10.44 Billion
XiaMen HongXin Electron-tech Co Ltd SHE:300657	China	CN¥6.73 Billion
Guangshen Railway Co Ltd SHG:601333	China	CN¥8.07 Billion
Qingdao Gon Technology Co Ltd SHE:002768	China	CN¥12.38 Billion
GOLDEN AGRI-RES ADR/100 F:4G3	Germany	€5.66 Billion
CareDx Inc NASDAQ:CDNA	USA	$107.39 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Sinopharm Group Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sinopharm Group Co. Ltd (X2S) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.41	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.05	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.66	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sinopharm Group Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sinopharm Group Co. Ltd (2013–2025)

The table below shows the annual total liabilities of Sinopharm Group Co. Ltd from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	€256.20 Billion ≈ $299.53 Billion	-3.74%
2024-12-31	€266.14 Billion ≈ $311.15 Billion	+1.17%
2023-12-31	€263.08 Billion ≈ $307.56 Billion	+3.29%
2022-12-31	€254.71 Billion ≈ $297.78 Billion	+8.04%
2021-12-31	€235.76 Billion ≈ $275.63 Billion	+6.54%
2020-12-31	€221.29 Billion ≈ $258.71 Billion	+14.69%
2019-12-31	€192.95 Billion ≈ $225.58 Billion	+15.20%
2018-12-31	€167.50 Billion ≈ $195.82 Billion	+41.62%
2017-12-31	€118.27 Billion ≈ $138.27 Billion	+4.50%
2016-12-31	€113.18 Billion ≈ $132.32 Billion	+14.84%
2015-12-31	€98.55 Billion ≈ $115.22 Billion	+6.70%
2014-12-31	€92.37 Billion ≈ $107.99 Billion	+20.20%
2013-12-31	€76.84 Billion ≈ $89.84 Billion	--

About Sinopharm Group Co. Ltd

F:X2S Germany Medical Distribution

Market Cap

$2.59 Billion

€2.21 Billion EUR

Market Cap Rank

#5362 Global

#853 in Germany

Share Price

€1.65

Change (1 day)

-0.57%

52-Week Range

€1.65 - €2.37

All Time High

€2.71